P101

P101 is one of the longer-established Italian venture firms, operating from Milan with a digital-first mandate that covers software, marketplaces, and increasingly digital health. The firm sits in a particular position in the Italian venture landscape: large enough to lead rounds, established enough to have multi-fund continuity, and Italian enough to be the natural reference for founders building primarily in or out of Italy.

The healthcare thesis covers digital health and health IT software, with a bias toward digital-first companies enhancing clinical workflows and societal wellbeing. The firm tends to favor B2B and B2C software companies operating at the intersection of consumer experience and clinical operations, rather than deeply regulated medical products. Specific portfolio companies are not enumerated in the source material, and founders should ask for healthcare-specific references in diligence to understand the firm’s actual cadence of engagement.

P101 invests at Series A and Series B, with checks of one to five million dollars and follow-on capacity through subsequent funds. The geographic focus is Italy with selective European activity, and the firm operates as a credible lead in Italian rounds and a meaningful syndicate partner in cross-border European deals. For digital health founders building primarily in the Italian market, P101 offers something that few other funds provide: the ability to anchor multiple rounds with an investor who understands the Italian healthcare system, payer environment, and commercial channels in depth.

The team is built around partners with backgrounds in operating, investing, and Italian technology entrepreneurship. Specific partner names are not provided in the source material, and founders should clarify which partner leads healthcare and how multi-fund continuation is handled in practice.

The right founders for P101 are digital health teams anchored in Italy with credible expansion plans into broader European markets, where the firm’s local depth and multi-stage continuity create genuine fit. The wrong founders are clinically regulated or device-led teams, where P101’s digital-first lens may not produce useful pressure. Founders should arrive with a clear view of the Italian commercial path, realistic assumptions about how the Italian healthcare system pays for digital products, and a credible plan to extend across at least one or two additional European markets. P101 rewards founders who treat Italy as a serious commercial market rather than a stepping stone, and tends to engage seriously with the operational realities of selling into the Italian system.